1. Home
  2. Directory
  3. New York
  4. Rochester
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1609893239

SABU THOMAS MD
Prescription History 1609893239
Internal Medicine - Cardiovascular Disease in Rochester, NY


Quality Rating: 90.23 out of 100 score

NPI Status: Active since July 17, 2006

Contact Information

601 ELMWOOD AVE
ROCHESTER, NY
ZIP 14642
Phone: (585) 275-4290
Fax: (585) 473-1573

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SABU THOMAS MD, an active Cardiovascular Disease specialist practicing in Rochester, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 90 documented patient claims. Among these therapy options, the most frequently utilized medication is Vyndamax, which accounts for 34 claims alone.

Medication Index

E
F
M
V
No matching medications currently found on file.

Entresto

Generic Formulation: Sacubitril/ValsartanSpecialty: Advanced Heart Failure and Transplant Cardiology
Provider Metrics Summary
Total Claims 27
30-Day Fills 29.0
Days Supply 840
NY State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills76.9
Peer Average Days Supply2,236
Conservative Utilization

This provider writes prescriptions for this formulation 41.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,659.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$728.13

State Avg Cost Per Claim

$1,026.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat certain types of heart failure. It may help you live longer and lower your chance of having to go to the hospital for heart failure. This product contains 2 medications: sacubitril and valsartan. Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.

Farxiga

Generic Formulation: Dapagliflozin PropanediolSpecialty: Advanced Heart Failure and Transplant Cardiology
Provider Metrics Summary
Total Claims 18
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills74.9
Peer Average Days Supply2,227
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,633.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$646.30

State Avg Cost Per Claim

$1,020.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. This medication is also used in people with type 2 diabetes and heart disease to lower the risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sugar by your kidneys. Dapagliflozin is also used to treat kidney disease and heart failure. It may help you live longer and lower your risk of going to the hospital for heart failure. Dapagliflozin works by increasing the removal of sodium by your kidneys.

Metoprolol Succinate

Generic Formulation: Metoprolol SuccinateSpecialty: Advanced Heart Failure and Transplant Cardiology
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.0
Days Supply 390
NY State Average Benchmarks
Peer Average Claims118.0
Peer Average 30-Day Fills269.4
Peer Average Days Supply7,996
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 90.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $123.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.24

State Avg Cost Per Claim

$20.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Therapeutic Applications

This medication is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart.

Vyndamax

Generic Formulation: TafamidisSpecialty: Advanced Heart Failure and Transplant Cardiology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills45.4
Peer Average Days Supply1,361
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $682,142.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,063.01

State Avg Cost Per Claim

$25,825.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of heart failure (transthyretin-mediated amyloidosis). It is used to help prevent the heart failure from getting worse and needing treatment in a hospital. Tafamidis works by slowing the buildup of a certain protein (amyloid fibrils) that causes heart problems.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SABU THOMAS MD provides transparency into local medical care patterns within Rochester, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Cardiovascular Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.